Literature DB >> 25676699

Efficacy and safety of rituximab in rheumatic diseases.

Eva Rath1, Jochen Zwerina, Bastian Oppl, Valerie Nell-Duxneuner.   

Abstract

B-cell depleting therapy is now in clinical use for more than 10 years in rheumatology. In 2001, a first report was published on five rheumatoid arthritis patients responding to the chimeric anti-CD20 antibody rituximab. Since then, numerous clinical trials, prospective and retrospective studies, registry data as well as case reports on the use of rituximab in autoimmune rheumatic diseases have been published. This review gives a short overview on clinical data of rituximab in rheumatic diseases currently available.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25676699     DOI： 10.1007/s10354-014-0331-8

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  71 in total

1.  Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab.

Authors:  D McGonagle; A L Tan; J Madden; A C Rawstron; A Rehman; P Emery; S Thomas
Journal:  Rheumatology (Oxford)       Date:  2008-02-15       Impact factor: 7.580

2.  Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion.

Authors:  Bryan R Whelan; David A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2009-03-01       Impact factor: 7.580

3.  Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

Authors:  Ioannnis Mitroulis; Chrisoula Hatzara; Anna Kandili; Emilia Hadziyannis; Dimitrios Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2012-08-28       Impact factor: 19.103

4.  Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.

Authors:  A Mekinian; P Ravaud; P Y Hatron; C Larroche; J Leone; B Gombert; M Hamidou; A Cantagrel; C Marcelli; S Rist; M Breban; D Launay; O Fain; J E Gottenberg; X Mariette
Journal:  Ann Rheum Dis       Date:  2011-09-16       Impact factor: 19.103

5.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.

Authors:  David B Clifford; Beau Ances; Craig Costello; Shari Rosen-Schmidt; Magnus Andersson; Deborah Parks; Arie Perry; Raju Yerra; Robert Schmidt; Enrique Alvarez; Kenneth L Tyler
Journal:  Arch Neurol       Date:  2011-05-09

6.  Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.

Authors:  Eamonn S Molloy; Leonard H Calabrese
Journal:  Arthritis Rheum       Date:  2009-12

7.  Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.

Authors:  V Smith; J T Van Praet; B Vandooren; B Van der Cruyssen; J-M Naeyaert; S Decuman; D Elewaut; F De Keyser
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

8.  Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.

Authors:  Jacques-Eric Gottenberg; Gael Cinquetti; Claire Larroche; Bernard Combe; Eric Hachulla; Olivier Meyer; Edouard Pertuiset; Guy Kaplanski; Laurent Chiche; Jean-Marie Berthelot; Bruno Gombert; Philippe Goupille; Christian Marcelli; Séverine Feuillet; Jean Leone; Jean Sibilia; Charles Zarnitsky; Philippe Carli; Stephanie Rist; Philippe Gaudin; Carine Salliot; Muriel Piperno; Adeline Deplas; Maxime Breban; Thierry Lequerre; Pascal Richette; Charles Ghiringhelli; Mohamed Hamidou; Philippe Ravaud; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2012-12-21       Impact factor: 19.103

9.  Remission achieved in refractory advanced takayasu arteritis using rituximab.

Authors:  D Ernst; M Greer; M Stoll; D Meyer-Olson; R E Schmidt; T Witte
Journal:  Case Rep Rheumatol       Date:  2012-10-10

10.  Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.

Authors:  P Emery; J E Gottenberg; A Rubbert-Roth; P Sarzi-Puttini; D Choquette; V M Martínez Taboada; L Barile-Fabris; R J Moots; A Ostor; A Andrianakos; E Gemmen; C Mpofu; C Chung; L Hinsch Gylvin; A Finckh
Journal:  Ann Rheum Dis       Date:  2014-01-17       Impact factor: 19.103
View more
  5 in total

Review 1.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

2.  Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey.

Authors:  Luca Bartolini; Eyal Muscal
Journal:  J Neurol       Date:  2017-02-02       Impact factor: 4.849

Review 3.  Biologic therapy in the idiopathic inflammatory myopathies.

Authors:  Thomas Khoo; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-11-04       Impact factor: 2.631

Review 4.  Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.

Authors:  Shivani Shah; Duvuru Geetha
Journal:  Immunotargets Ther       Date:  2015-08-07

5.  Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders.

Authors:  Andrea Marcinnò; Fabiana Marnetto; Paola Valentino; Serena Martire; Alessia Balbo; Aurora Drago; Maria Leto; Marco Capobianco; Giancarlo Panzica; Antonio Bertolotto
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.